Ocuphire Pharma Q1 2024 GAAP EPS $(0.29) Misses $(0.13) Estimate
Portfolio Pulse from Benzinga Newsdesk
Ocuphire Pharma reported a Q1 2024 GAAP EPS loss of $(0.29), missing the analyst consensus estimate of $(0.13) by 123.08%.
May 10, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ocuphire Pharma's Q1 2024 earnings missed analyst estimates significantly, reporting a loss of $(0.29) per share against an expected $(0.13).
Earnings misses typically lead to negative investor sentiment in the short term, potentially causing a decrease in stock price. Given the significant miss against analyst expectations, this is likely to be the case for OCUP.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100